Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 1;10(11):1588-1590.
doi: 10.1001/jamaoncol.2024.3683.

Radiation-Associated Secondary Cancer in Patients With Breast Cancer Harboring TP53 Germline Variants

Gustav Y Cederquist  1 , Lillian A Boe  2 , Michael Walsh  3 , Gary M Freedman  4 , Kara N Maxwell  5 , Neil Taunk  4 , Lior Z Braunstein  1
Affiliations

Radiation-Associated Secondary Cancer in Patients With Breast Cancer Harboring TP53 Germline Variants

Gustav Y Cederquist et al. JAMA Oncol. .
No abstract available

Plain language summary

This cohort study examines the risk of radiation-associated sarcoma in patients with breast cancer harboring germline TP53 variants.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: None reported.

Figures

Figure.
Figure.. Secondary Cancer Risk
A, In-field sarcoma after breast radiotherapy (RT) in TP53 pathogenic variance (PV) carriers. The 15-year cumulative incidence risk of developing an in-field sarcoma after breast RT in patients with TP53 PV was 8.8% (IQR, 1.4%-25%). The 15-year risk of the control cohort was 0.0% (P < .001). B, The 10-year cumulative risk of any secondary cancer was not significantly different between TP53 PV carriers who received RT (22.5% [95% CI, 8.8%-40.0%]) and RT-naive PV carriers (38% [95% CI, 15.4%-61%]) (P = .55). The shaded areas indicate 95% CIs.
See this image and copyright information in PMC

References

    1. Heymann S, Delaloge S, Rahal A, et al. Radio-induced malignancies after breast cancer postoperative radiotherapy in patients with Li-Fraumeni syndrome. Radiat Oncol. 2010;5:104. doi: 10.1186/1748-717X-5-104 - DOI - PMC - PubMed
    1. Le AN, Harton J, Desai H, et al. Frequency of radiation-induced malignancies post-adjuvant radiotherapy for breast cancer in patients with Li-Fraumeni syndrome. Breast Cancer Res Treat. 2020;181(1):181-188. doi: 10.1007/s10549-020-05612-7 - DOI - PMC - PubMed
    1. Petry V, Bonadio RC, Cagnacci AQC, et al. Radiotherapy-induced malignancies in breast cancer patients with TP53 pathogenic germline variants (Li-Fraumeni syndrome). Fam Cancer. 2020;19(1):47-53. doi: 10.1007/s10689-019-00153-5 - DOI - PubMed
    1. Veiga LHS, Vo JB, Curtis RE, et al. Treatment-related thoracic soft tissue sarcomas in US breast cancer survivors: a retrospective cohort study. Lancet Oncol. 2022;23(11):1451-1464. doi: 10.1016/S1470-2045(22)00561-7 - DOI - PMC - PubMed
    1. Taghian A, de Vathaire F, Terrier P, et al. Long-term risk of sarcoma following radiation treatment for breast cancer. Int J Radiat Oncol Biol Phys. 1991;21(2):361-367. doi: 10.1016/0360-3016(91)90783-Z - DOI - PubMed